- Home
- HCM vs TMDX Comparison
HCM vs TMDX Comparison
Compare HCM & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCM
- TMDX
- Stock Information
- Founded
- HCM 2000
- TMDX 1998
- Country
- HCM Hong Kong
- TMDX United States
- Employees
- HCM N/A
- TMDX N/A
- Industry
- HCM Biotechnology: Pharmaceutical Preparations
- TMDX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- HCM Health Care
- TMDX Health Care
- Exchange
- HCM Nasdaq
- TMDX Nasdaq
- Market Cap
- HCM 2.6B
- TMDX 2.1B
- IPO Year
- HCM N/A
- TMDX 2019
- Fundamental
- Price
- HCM $14.20
- TMDX $57.20
- Analyst Decision
- HCM Hold
- TMDX Buy
- Analyst Count
- HCM 1
- TMDX 11
- Target Price
- HCM $19.00
- TMDX $116.10
- AVG Volume (30 Days)
- HCM 76.1K
- TMDX 2.5M
- Earning Date
- HCM 02-26-2025
- TMDX 02-24-2025
- Dividend Yield
- HCM N/A
- TMDX N/A
- EPS Growth
- HCM N/A
- TMDX N/A
- EPS
- HCM N/A
- TMDX 0.94
- Revenue
- HCM $610,806,000.00
- TMDX $401,090,000.00
- Revenue This Year
- HCM N/A
- TMDX $81.61
- Revenue Next Year
- HCM $20.69
- TMDX $22.52
- P/E Ratio
- HCM N/A
- TMDX $61.04
- Revenue Growth
- HCM N/A
- TMDX 109.09
- 52 Week Low
- HCM $11.93
- TMDX $56.03
- 52 Week High
- HCM $21.92
- TMDX $177.37
- Technical
- Relative Strength Index (RSI)
- HCM 42.32
- TMDX 35.74
- Support Level
- HCM $13.00
- TMDX $58.40
- Resistance Level
- HCM $15.29
- TMDX $67.80
- Average True Range (ATR)
- HCM 0.46
- TMDX 4.59
- MACD
- HCM -0.00
- TMDX -0.27
- Stochastic Oscillator
- HCM 37.74
- TMDX 4.44
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
About TMDX TransMedics Group Inc.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.